Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Oct 30;39(ACS-5):1-52.
doi: 10.14745/ccdr.v39i00a05.

Statement on the Use of Conjugate Pneumococcal Vaccine - 13 Valent in Adults (Pneu-C-13): An Advisory Committee Statement (ACS) National Advisory Committee on Immunization (NACI)

C Quach-Thanh, Ms H Thomas; approved by NACI.

Statement on the Use of Conjugate Pneumococcal Vaccine - 13 Valent in Adults (Pneu-C-13): An Advisory Committee Statement (ACS) National Advisory Committee on Immunization (NACI)

C Quach-Thanh et al. Can Commun Dis Rep. .
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
Reported number of cases and incidence rate of invasive pneumococcal disease, Canada, 2001–2011 * Data obtained from the Canadian Notifiable Disease Surveillance System † Based on preliminary data
Figure 2
Figure 2
Mean number of cases and mean incidence rate of invasive pneumococcal disease (per 100,000 population), by province and territory, Canada, 2007–2011
Figure 3
Figure 3
Mean annual incidence of invasive pneumococcal disease by province and territory – all age groups (per 100,000 population), pre and post PNEU-C-7 implementation, Canada, 2001–2011 *Data obtained from the Canadian Notifiable Disease Surveillance System (Preliminary data from 2009–2011) **The year in which the program was initiated is included in pre-implementation. Data were available from 2001 to 2011 for all Provinces /Territories.
Figure 4
Figure 4
Incidence rate of invasive pneumococcal disease in < 20 years old, by age group and year, Canada, 2001–2011 * Data obtained from the Canadian Notifiable Disease Surveillance System † Based on preliminary data Note: PNEU-C-10 was introduced in some Canadian provinces and territories in 2009.
Figure 5
Figure 5
Incidence rate of IPD cases aged 20 years and older, by age group and year, Canada, 2001–2011 *Data obtained from the Canadian Notifiable Disease Surveillance System. † Based on preliminary data
Figure 6
Figure 6
Regional distribution of S. pneumoniae serotypes in Canada, 2011
Figure 7
Figure 7
Proportion of PNEU-C-7 serotypes by age group, 2010–2011
Figure 8
Figure 8
Proportion of PNEU-C-13 serotypes by age group, 2010–2011
Figure 9
Figure 9
Proportion of PNEU-P-23 serotypes by age group, 2010–2011
See this image and copyright information in PMC

References

    1. National Advisory Committee on Immunization. An Advisory Committee Statement (ACS). National Advisory Committee on Immunization (NACI). Statement on recommended use of pneumococcal conjugate vaccine. Can Commun Dis Rep 2002. Jan;28 ACS-2:1–32. - PubMed
    1. National Advisory Committee on Immunization (NACI); An Advisory Committee Statement (ACS). Update on the recommendations for the routine use of pneumococcal conjugate vaccine for infants. Can Commun Dis Rep 2006. May;32 ACS-4:1–6.
    1. National Advisory Committee on Immunization (NACI). Update on the Use of Pneumococcal Vaccines in Childhood. Can Commun Dis Rep 2010;36(ACS-12):1–21. - PMC - PubMed
    1. National Advisory Committee on Immunization (NACI); An Advisory Committee Statement (ACS). Evidence-based recommendations for immunization--methods of the National Advisory Committee on Immunization. Can Commun Dis Rep 2009. Jan;35 ACS-1:1–10. - PubMed
    1. World Health Organization. Pneumococcal Disease. 2012; www.who.int/ith/diseases/pneumococcal/en/index.html